Home/Filings/4/0001607062-21-000049
4//SEC Filing

PETKANAS DEAN 4

Accession 0001607062-21-000049

CIK 0001615999other

Filed

Mar 15, 8:00 PM ET

Accepted

Mar 16, 4:47 PM ET

Size

10.4 KB

Accession

0001607062-21-000049

Insider Transaction Report

Form 4
Period: 2021-03-12
PETKANAS DEAN
DirectorChief Executive Officer10% Owner
Transactions
  • Award

    Common Stock

    2021-03-12$0.13/sh+192,308$25,00023,594,432 total(indirect: See Note)
  • Award

    Common Stock

    2021-03-12$0.13/sh+692,308$90,00022,984,029 total(indirect: See Note)
  • Award

    Employee Stock Option

    2021-03-12+1,450,0001,450,000 total
    Exercise: $0.13Exp: 2031-03-11Common Stock (1,450,000 underlying)
Footnotes (4)
  • [F1]The reporting person agreed to accept 692,308 restricted shares of the issuers common stock in exchange for the discharge of an aggregate of $90,000 of accrued but unpaid monies payable by the issuer to the reporting person as a portion of his salary. The issuance was approved by the issuers board of directors on March 12, 2021. The price of the shares acquired by the reporting person is equal to the closing price of the Companys common stock on March 11, 2021, which was $0.13.
  • [F2]Aggregate amount of shares beneficially owned by the reporting person includes shares held by him directly as well as indirectly through Powerlife Phytomedical, LLC and Golden Gate Capital Partners, LLC. The reporting person disclaims beneficial ownership of the securities held by Powerlife Phytomedical, LLC and Golden Gate Capital Partners, LLC, except to the extent of his pecuniary interest therein.
  • [F3]Golden Gate Capital Partners, LLC agreed to accept 192,308 restricted shares of the issuer's common stock in exchange for the discharge of an aggregate of $25,000 of accrued but unpaid corporate expenses payable by the issuer to Golden Gate Capital Partners, LLC. The issuance was approved by the issuer's board of directors on March 12, 2021. The price of the shares acquired by Golden Gate Capital Partners, LLC is equal to the closing price of the Company's common stock on March 11, 2021, which was $0.13.
  • [F4]1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months thereafter.

Issuer

NEUROPATHIX, INC.

CIK 0001615999

Entity typeother

Related Parties

1
  • filerCIK 0000944235

Filing Metadata

Form type
4
Filed
Mar 15, 8:00 PM ET
Accepted
Mar 16, 4:47 PM ET
Size
10.4 KB